Womed Fundraising

THM Capital Advisory supports WOMED in raising its €6 million Series A from private investors and the French fund IRDI.
‍

​Activity

WOMED is a Femtech startup developing innovative, safe and effective treatments to fight infertility and uterine pathologies.

The company was founded by Gonzague Issenmann, Prof. Xavier Garric and Dr. Stephanie Huberlant, to commercialize an invention from the “Polymers for Health and Biomaterials” laboratory at the University of Montpellier.

Womed Leaf™ is a medical device intended to treat and prevent uterine wall attachment after surgery (intrauterine adhesions), associated with infertility and obstetric complications such as abnormal placentation.

Womed Leaf™ has obtained CE marking under new European regulations, and clinical trial efficacy data is due to be presented in H1 2024.

Based on its proprietary polymer technology, WOMED is also developing therapies for intrauterine drug delivery for fibroids, endometriosis, and acute bleeding.
‍

Objectives

Series A funds the commercial launch of Leaf™ and the continued development of the portfolio of proprietary intrauterine therapies, including the pre-clinical study of fibroid treatment.
‍

Investors

Private investors (family offices and business angels) and the regional fund IRDI Capital Investissement.